Chronic DiseasesImmunologyHematologyHealth DiagnosticsInfectious DiseasesPulmonologyGeneticsBiotechnologyHealth Care
Description
Grifols, S.A. (Grifols) is a global specialty plasma therapeutics company.
The company is developing, manufacturing, and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in hu…
Analysis
Hidden champion
Grifols, S.A. fits the profile of a hidden champion, yet the market has not awarded it the premium its quality earns.
On valuation, the picture is attractive. The owner-earnings multiple stands at 12.1×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around -0% a year, against analyst forecasts of 24%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is fragile. The company scores 12/20 on our value-creation score: creating some value.
Flags to be aware of: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Feb 202698
84
2026
All-time high
98
Feb 2026
All-time low
74
Mar 2026
Average rank
85
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
97
—
—
—
Price/Earnings
31
—
—
—
Price/Book
63
—
—
—
Dividend Yield
99
—
—
—
Value (overall)
99
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.